ABEO — Abeona Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $263.91m
- $76.55m
- 34
- 62
- 52
- 48
Annual income statement for Abeona Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10 | 3 | 1.41 | 3.5 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 91.4 | 91.1 | 52.3 | 50.6 | 64.2 |
| Operating Profit | -81.4 | -88.1 | -50.9 | -47.1 | -64.2 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -84.2 | -84.9 | -39.7 | -54.2 | -63.7 |
| Net Income After Taxes | -84.2 | -84.9 | -39.7 | -54.2 | -63.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -84.2 | -84.9 | -39.7 | -54.2 | -63.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -84.2 | -84.9 | -43.5 | -54.2 | -63.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13.8 | -15.5 | -4.81 | -2.58 | -1.55 |